Ground Swell Capital LLC Acquires New Position in bioAffinity Technologies, Inc. (NASDAQ:BIAF)

Ground Swell Capital LLC bought a new position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned 0.20% of bioAffinity Technologies at the end of the most recent quarter.

Wall Street Analyst Weigh In

Separately, Maxim Group started coverage on bioAffinity Technologies in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $6.00 price target on the stock.

bioAffinity Technologies Stock Performance

Shares of BIAF opened at $1.39 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.15 and a debt-to-equity ratio of 0.19. bioAffinity Technologies, Inc. has a 52-week low of $0.95 and a 52-week high of $3.62. The company has a 50-day simple moving average of $2.01 and a 200-day simple moving average of $2.15. The company has a market capitalization of $18.75 million, a PE ratio of -1.49 and a beta of 2.94.

bioAffinity Technologies (NASDAQ:BIAF) last issued its earnings results on Wednesday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter. The company had revenue of $2.40 million during the quarter. bioAffinity Technologies had a negative net margin of 120.76% and a negative return on equity of 172.06%.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.